List of Excipients in Branded Drug MYCOPHENOLIC ACID

« Back to Dashboard

Generic Drugs Containing MYCOPHENOLIC ACID

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	mycophenolic acid	0093-7031	ALUMINUM OXIDE
Teva Pharmaceuticals USA Inc	mycophenolic acid	0093-7031	ANHYDROUS LACTOSE
Teva Pharmaceuticals USA Inc	mycophenolic acid	0093-7031	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	mycophenolic acid	0093-7031	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in MYCOPHENOLIC ACID?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
5	AMMONIA
15	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE

Mycophenolic Acid Excipient Strategy and Commercial Opportunities

Last updated: November 5, 2026

Mycophenolic acid (MPA) has a mature, genericized market in which excipient selection remains commercially relevant. The strongest opportunities are delayed-release systems, pediatric liquids, taste-masked suspensions, low-impurity excipient platforms, and manufacturing technologies that improve dissolution consistency and stability. Patent barriers are limited in the United States because the principal CellCept and Myfortic exclusivity periods have expired, but formulation-specific patents, regulatory requirements, and clinical interchangeability constraints still affect market entry.

What pharmaceutical products contain mycophenolic acid?

MPA is marketed principally through two oral product strategies:

Product	Active form	Dosage form	Core formulation strategy	Originator
CellCept	Mycophenolate mofetil, a prodrug of MPA	Tablets, capsules, oral suspension	Immediate-release conversion to MPA after absorption	Roche/Genentech
Myfortic	Mycophenolate sodium	Delayed-release enteric-coated tablets	Release protection through the stomach and intestinal delivery of MPA	Novartis
Generic products	Mycophenolate mofetil or mycophenolic acid	Tablets, capsules, suspension, delayed-release tablets	Follow-on versions of the originator dosage forms	Multiple manufacturers

CellCept is not chemically identical to Myfortic. Mycophenolate mofetil is the 2-morpholinoethyl ester prodrug of MPA. Mycophenolate sodium is the sodium salt of MPA used in an enteric-coated delayed-release tablet.

The distinction matters commercially. A manufacturer developing an immediate-release mycophenolate mofetil product competes primarily on cost, supply reliability, suspension performance, and manufacturing efficiency. A manufacturer developing delayed-release mycophenolic acid must manage enteric performance, dissolution equivalence, tablet robustness, and regulatory expectations for a more complex dosage form.

What excipients are used in CellCept and Myfortic?

The originator products use conventional tablet and coating excipients, but the performance requirements differ materially.

CellCept excipient platform

CellCept tablets use standard direct-compression or granulation excipients, including:

• Microcrystalline cellulose
• Povidone
• Croscarmellose sodium
• Magnesium stearate
• Film-coating polymers
• Polyethylene glycol
• Titanium dioxide
• Iron oxides, depending on strength

CellCept oral suspension uses a separate excipient system designed for aqueous dispersion, palatability, microbial control, and redispersibility. The formulation includes suspending and buffering components, sweetening or flavor-related ingredients, and sodium benzoate as a preservative in the marketed product information. Exact excipient composition varies by jurisdiction and presentation (Genentech, 2023).

The commercial challenge is less the tablet core than the liquid. Mycophenolate mofetil suspension must maintain dose uniformity after reconstitution, resist sedimentation and caking, and remain acceptable to pediatric and transplant patients.

Myfortic excipient platform

Myfortic delayed-release tablets use a conventional tablet core combined with an enteric coating. Listed excipients include:

• Lactose
• Crospovidone
• Povidone
• Colloidal silicon dioxide
• Magnesium stearate
• Starch-based excipients
• Hypromellose or related film-forming polymers
• Methacrylic acid copolymer
• Talc
• Triethyl citrate
• Iron oxide colorants

The functional excipient group is the enteric coating. Methacrylic acid copolymers provide pH-dependent dissolution, while triethyl citrate acts as a plasticizer and talc supports coating processability. Coating weight gain, polymer grade, plasticizer ratio, and curing conditions directly affect gastric resistance and intestinal release (Novartis, 2023).

Which excipient functions create the strongest commercial opportunities?

The most valuable excipient opportunities are tied to clinical and manufacturing problems rather than simple substitution of one filler for another.

Opportunity	Primary problem addressed	Commercial attractiveness
Enteric polymer systems	Gastric protection and delayed intestinal release	High
Pediatric suspension systems	Taste, settling, dose uniformity, microbial stability	High
Low-peroxide excipient grades	Oxidative degradation and impurity control	Medium to high
Direct-compression platforms	Cost, throughput, tablet weight control	Medium
Co-processed excipients	Flow, compaction, reduced process variability	Medium
Taste-masking systems	Pediatric adherence and oral acceptability	High
Moisture-control systems	Stability of tablets and coatings	Medium
Functional capsule materials	Dissolution and product differentiation	Low to medium

Enteric coating systems

Delayed-release MPA is the highest-value formulation segment for excipient suppliers. The coating must resist dissolution under acidic conditions and release the drug at intestinal pH. Important variables include:

• Methacrylic acid copolymer type
• Polymer molecular weight
• Neutralization level
• Plasticizer selection
• Talc or anti-tacking concentration
• Coating thickness
• Curing temperature and duration
• Tablet porosity and core disintegration

The best commercial position is a validated enteric platform that can support bioequivalence development and scale-up. Suppliers offering ready-to-use aqueous dispersions, controlled particle-size polymers, and low-variability plasticizer systems can reduce formulation development time.

A simple polymer substitution is unlikely to create durable differentiation. The product must meet dissolution requirements across multiple pH stages while maintaining tablet stability under accelerated and long-term storage conditions.

Pediatric suspension systems

Pediatric and geriatric transplant populations create a continuing opportunity for improved liquid products. The key attributes are:

• Accurate dosing at low volumes
• Rapid and complete redispersion
• Low sedimentation rate
• Reduced caking
• Acceptable taste
• Chemical stability after reconstitution
• Broad storage tolerance
• Preservative compatibility
• Low risk of dosing-device interaction

Potential excipient approaches include structured suspending systems based on xanthan gum, microcrystalline cellulose and carboxymethylcellulose combinations, or other low-viscosity polymers. These systems must balance suspension performance with syringeability. Excessive viscosity increases dosing errors and reduces caregiver acceptance.

Taste masking is commercially meaningful because mycophenolate products can have an unpleasant taste profile. Ion-exchange resins, lipid-based barriers, polymeric coatings, and flavor-compatible pH adjustment can support pediatric positioning. Any taste-masking system must avoid delaying or reducing absorption after administration.

How does mycophenolate mofetil compare with delayed-release mycophenolic acid?

Attribute	Mycophenolate mofetil	Mycophenolate sodium delayed-release
Prodrug or active salt	Prodrug	Active MPA salt
Typical release profile	Immediate release	Enteric delayed release
Main excipient challenge	Suspension, flow, stability, taste	Enteric coating and dissolution
Primary dosage forms	Tablet, capsule, suspension	Enteric-coated tablet
Development complexity	Moderate	High
Pediatric flexibility	Stronger because of suspension	More limited because of tablet form
Key differentiation route	Liquid performance and manufacturing cost	Coating performance and GI tolerability
Generic competition	Broad	Narrower but technically more complex

These products should not be treated as automatically interchangeable from a formulation or commercial perspective. FDA labeling states that mycophenolate mofetil and delayed-release mycophenolic acid products have different pharmacokinetic profiles and should not be substituted without appropriate clinical and regulatory authorization (FDA, 2023a; FDA, 2023b).

What FDA regulatory status and Orange Book protections apply?

CellCept and Myfortic are approved U.S. prescription products. CellCept is approved in several oral presentations, including tablets, capsules, and oral suspension. Myfortic is approved as delayed-release tablets for immunosuppression in transplant recipients.

The principal regulatory pathways are:

• Abbreviated New Drug Application for generic mycophenolate mofetil products
• ANDA for generic delayed-release mycophenolic acid tablets
• 505(b)(2) application for a materially modified dosage form, new route, pediatric formulation, or differentiated release system
• New drug application or supplemental NDA for a major reformulation by the originator

The U.S. Orange Book has historically listed patents and exclusivity associated with the originator products. The principal product and formulation patents associated with CellCept and Myfortic have expired, and current entry barriers are primarily regulatory, technical, and commercial rather than basic composition-of-matter protection (FDA, 2024).

Patent status must be assessed at the specific product and presentation level. A formulation company should separately review:

1. Current Orange Book-listed patents.
2. Unlisted formulation and manufacturing patents.
3. Patent-term adjustment and pediatric exclusivity history.
4. Paragraph IV certifications filed against relevant products.
5. Federal district court litigation and settlement terms.
6. Patent coverage in Europe, Japan, Canada, China, and major transplant markets.

When did mycophenolate products lose exclusivity?

The central U.S. exclusivity periods have passed.

Product or protection	Commercial relevance	Current position
CellCept composition and core product protection	Protected the original mycophenolate mofetil product	Expired
CellCept formulation and presentation patents	Covered dosage forms and related formulations	Expired or no longer a primary U.S. barrier
Myfortic delayed-release formulation patents	Covered enteric delivery and related dosage forms	Historical protection largely expired
Pediatric exclusivity	Added time to certain listed protections	Expired
Regulatory exclusivity	Limited period for reliance on originator data	Expired

The expired patent estate does not eliminate development risk. Generic applicants still must establish bioequivalence, meet dissolution specifications, satisfy current good manufacturing practice requirements, and address product-specific FDA review comments.

Are there Paragraph IV challenges to mycophenolate products?

Paragraph IV activity has been associated with generic entry into CellCept and Myfortic-related markets. The major commercial effect of those challenges was to accelerate the transition from originator supply to multi-source generic supply after expiration of the relevant patents.

For current development, the commercial question is less whether a basic Paragraph IV opportunity exists and more whether the product offers a credible advantage over established generics. Potential advantages include:

• Lower manufacturing cost
• More reliable API and excipient supply
• Improved suspension shelf life
• Better taste and dosing performance
• Reduced tablet defects
• Faster dissolution development
• Regional manufacturing capability
• Dual sourcing for transplant programs

A Paragraph IV strategy directed only at an expired or weak formulation patent is unlikely to generate substantial value. A stronger strategy combines an ANDA or 505(b)(2) pathway with proprietary manufacturing know-how, a differentiated presentation, or a new patient-use profile.

What patent opportunities remain for mycophenolic acid excipients and formulations?

The most defensible patent opportunities are narrow and process-oriented.

Formulation patents

Potential claims may cover:

• Specific enteric polymer combinations
• Defined coating weight and plasticizer ratios
• pH-triggered release profiles
• Low-dose pediatric suspensions
• Taste-masked particles or granules
• Redispersible oral suspension systems
• Excipient systems that reduce degradation products
• Moisture-resistant tablet coatings
• Unit-dose liquid presentations
• Stable premixes for hospital compounding

A broad claim to “MPA plus an enteric polymer” would face substantial prior-art pressure. Claims tied to measurable dissolution, impurity limits, storage performance, or a specific manufacturing sequence have a stronger prospect of surviving examination.

Manufacturing and process patents

Process protection may cover:

• Fluid-bed coating conditions
• Solvent-free coating methods
• Continuous manufacturing
• Low-shear granulation
• Controlled particle-size distribution
• API-excipient premixing
• Curing profiles
• Removal of residual solvents
• Protection from peroxide-driven oxidation

Manufacturing patents are particularly relevant where excipient variability affects dissolution or degradation. They can also create practical barriers that are difficult to identify from the final product label.

Which companies are positioned in the mycophenolate market?

The market includes originators, generic pharmaceutical manufacturers, API producers, and excipient suppliers.

Originator and branded companies

Roche and Genentech are associated with CellCept. Novartis is associated with Myfortic. These products retain commercial relevance in transplant prescribing, hospital formularies, and physician familiarity even after generic entry.

Generic manufacturers

The generic market includes multiple manufacturers of mycophenolate mofetil tablets, capsules, oral suspension, and delayed-release mycophenolic acid tablets. Competition is generally based on:

• Price
• FDA approval status
• Supply continuity
• Wholesaler and group-purchasing access
• Contract manufacturing
• Product availability by strength
• Formulary position

Excipient suppliers

Commercially relevant suppliers include manufacturers of:

• Methacrylic acid copolymers
• Cellulosic film-coating polymers
• Plasticizers
• Suspending agents
• Co-processed compression excipients
• Low-peroxide grades of povidone and other polymers
• Pharmaceutical-grade surfactants
• Taste-masking polymers

The highest-value supplier model is technical partnership. A supplier that provides formulation support, coating-process development, regulatory documentation, and multiple regional manufacturing sites has a stronger position than a commodity excipient seller.

What geographic opportunities exist?

The United States and Western Europe are mature markets with extensive generic competition. Growth opportunities are more likely in:

• Asia-Pacific transplant centers
• Latin America
• Middle East markets
• Countries with limited access to delayed-release products
• Markets where pediatric liquid supply is inconsistent
• Regions dependent on imported finished dosage forms

Geographic differentiation can come from localized excipient sourcing, heat- and humidity-stable formulations, smaller pack sizes, and products compatible with local reconstitution practices.

Excipient selection must account for regional regulatory acceptance. A formulation using a novel polymer, colorant, preservative, or taste-masking agent may require additional justification in one jurisdiction even if it is accepted in another. The regulatory burden is highest when the excipient lacks broad oral-use precedent or when the finished product is intended for pediatric patients.

What generic launch risks exist for mycophenolic acid?

The principal launch risks are operational and regulatory.

Risk	Effect on launch
Dissolution failure	Delays approval or requires reformulation
Poor coating adhesion	Causes stability and dose-release failures
Excipient lot variability	Creates batch-to-batch performance differences
Suspension caking	Produces inaccurate dosing
Unacceptable taste	Reduces pediatric uptake
API impurity growth	Limits shelf life
Weak supply continuity	Causes formulary loss
Product switching concerns	Limits substitution in transplant patients
Device incompatibility	Creates dosing problems for oral liquids
Low margin	Reduces commercial value despite approval

Transplant products also carry a higher consequence for supply interruption than many primary-care generics. Manufacturers and hospital buyers often value dual sourcing, safety stock, and consistent batch release. A low-cost product without reliable availability may not secure durable market share.

How strong is the patent estate for mycophenolic acid?

The basic patent estate is weak for new U.S. entrants because the foundational product and formulation protections have expired. The remaining opportunity is a secondary patent estate focused on:

• Enteric delivery
• Pediatric formulations
• Taste masking
• Stability
• Manufacturing
• Packaging
• Combination regimens
• Specific release profiles

Patent strength depends on claim specificity and experimental support. A formulation patent supported only by routine excipient substitution is vulnerable to obviousness challenges. A patent supported by unexpected dissolution behavior, improved stability, reduced variability, or clinically relevant tolerability has greater commercial value.

The most defensible strategy is to combine a low-risk generic pathway with separate intellectual property covering a differentiated formulation or manufacturing process.

Is there biosimilar risk for mycophenolic acid?

Biosimilar risk does not apply. MPA is a small-molecule immunosuppressant, not a biologic. Competition comes through generic-drug pathways, not biosimilar applications.

This distinction affects development cost, approval timing, interchangeability, and patent strategy. A company does not need to establish biosimilarity, but it must establish pharmaceutical equivalence and bioequivalence or otherwise justify the selected regulatory pathway.

What licensing and partnering opportunities exist?

The most practical licensing opportunities are likely to involve technology rather than the active pharmaceutical ingredient.

Potential deal structures include:

• Licensing an enteric coating platform to a generic manufacturer
• Supplying a proprietary pediatric suspension system
• Co-developing a 505(b)(2) formulation
• Licensing taste-masking technology for hospital and pediatric use
• Providing a dual-source excipient package
• Contract manufacturing of delayed-release tablets
• Regional commercialization rights for emerging markets
• Supplying validated low-peroxide or low-moisture excipients

Roche’s CellCept franchise and Novartis’s Myfortic franchise are originator assets, but the strongest current partnering logic is with generic manufacturers, specialty transplant companies, and excipient suppliers rather than with the original brands.

Key Takeaways

• Mycophenolic acid is a mature generic market with meaningful formulation opportunities.
• Mycophenolate mofetil and delayed-release mycophenolate sodium require different excipient strategies.
• Enteric coatings are the highest-value technical segment for delayed-release products.
• Pediatric suspension, taste masking, and redispersibility are the strongest patient-facing opportunities.
• Core CellCept and Myfortic patent barriers have largely expired in the United States.
• Current differentiation depends on dissolution control, stability, supply reliability, and regulatory execution.
• Biosimilar competition does not apply because MPA is a small molecule.
• The strongest IP opportunities are narrow claims covering coating systems, release profiles, pediatric formulations, stability, and manufacturing.
• Commercial success is more likely through excipient technology licensing, contract development, or differentiated generic products than through a basic me-too tablet.

FAQs

What is the best excipient for a delayed-release mycophenolic acid tablet?

Methacrylic acid copolymers are the principal enteric-polymer class used for delayed intestinal release. The optimal grade depends on the target dissolution profile, coating process, plasticizer, tablet core, and regulatory strategy.

Can mycophenolate mofetil be formulated as a pediatric liquid?

Yes. Mycophenolate mofetil oral suspension is an established dosage form. The main development issues are taste, redispersibility, chemical stability, preservative performance, and dose accuracy.

Is a new excipient required for a differentiated mycophenolic acid product?

No. Differentiation can be achieved with established excipients through a novel ratio, coating process, release profile, suspension architecture, packaging system, or manufacturing method.

Does a new mycophenolic acid formulation require a 505(b)(2) application?

Not necessarily. A conventional generic equivalent may proceed through an ANDA. A materially different release profile, route, dosage form, or clinical use may require a 505(b)(2) application.

What is the most attractive commercial niche for MPA excipients?

The strongest niche is a validated platform combining enteric coating performance with manufacturing support. Pediatric suspension and taste-masking systems rank next because they address adherence and dosing problems not solved by standard tablets.

References

1. Genentech USA, Inc. (2023). CellCept (mycophenolate mofetil) prescribing information. U.S. Food and Drug Administration.

2. Novartis Pharmaceuticals Corporation. (2023). Myfortic (mycophenolic acid) delayed-release tablets prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2023a). CellCept and generic mycophenolate mofetil drug labeling. Drugs@FDA.

4. U.S. Food and Drug Administration. (2023b). Myfortic and delayed-release mycophenolic acid drug labeling. Drugs@FDA.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2022). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. U.S. Department of Health and Human Services.

7. European Medicines Agency. (2023). Myfortic: Summary of product characteristics. European Union.